Lipids & metabolic liver disease
Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
Authors' conclusion
The combination of ISM1 with TG and UA was identified as the best predictive factor for diagnosing MAFLD and MetS, potentially due to their contribution to aggravating the metabolic state.
Study context
- Population
- Patients with T2D and/or MAFLD and healthy controls4 groups
- Participants
- 250 patients
- Exposure
- T2D with MAFLD, newly diagnosed T2D, MAFLD vs healthy controls
- T2DM and MAFLDn = 60
- Newly diagnosed T2DMn = 60
- MAFLDn = 60
- Healthy controlsn = 70reference
- Outcome
- Relationship between serum ISM1 and MAFLD in T2D, and involvement of MetS
Methodological detailsSerum ISM1 measured by ELISA; Cochran-Armitage trend test across ISM1 quartiles
- Serum ISM1 measured by ELISA; Cochran-Armitage trend test across ISM1 quartiles
Main finding
As reported in the abstract
Serum ISM1
- Serum ISM1 significantly elevated in patients with coexisting MAFLD, MetS and T2D vs controls
- Relative risks for MAFLD, T2D and T2D with MAFLD increased significantly with higher ISM1 quartiles
- Serum ISM1 positively correlated with number of MetS components
Observational data: associations, not effects.
Further findings
Serum ISM1 by body mass index (BMI) category
- Higher in overweight/obese than lean
Correlates of serum ISM1
- Positively correlated with BMI, uric acid, ALT, AST, total cholesterol (TC), LDL-C, fasting insulin, HOMA-IR; negatively with age and high-density lipoprotein cholesterol (HDL-C)
- BMI, TC and HDL-C independently associated with serum ISM1
Original publication
Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus. BMJ Open Diabetes Res Care. Published 25 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →